(RTTNews) - Johnson & Johnson (JNJ) announced that updated results from the Phase 3 MARIPOSA-2 study showed that combining RYBREVANT (amivantamab-vmjw) with chemotherapy provided consistent ...

J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and clinically meaningful improvement to survival relative to Tagrisso in a pivotal trial.

Johnson & Johnson (NYSE:JNJ) announced that a Phase 2 open-label trial for its lung cancer therapy Rybrevant reached the primary endpoint related to infusion-related reactions following ...

The approval allows the use of the cancer drug, Rybrevant, in combination with J&J's existing drug, lazertinib, as a first-line treatment for non-small cell lung cancer (NSCLC) patients with a ...